Financings in Brief: Genelabs Technologies
This article was originally published in The Gray Sheet
Executive SummaryGenelabs Technologies: Firm's joint venture with the government of Taiwan, Genelabs Biotechnology Ltd., completes $14.6 mil. initial phase of financing. The venture, in which Genelabs has 40% interest, Taiwan 35% and private investors 25%, "plans to focus on the late stage development, manufacture and commercialization of newly developed or formulated pharmaceuticals, vaccines and other health care products for the Asian market," Genelabs states. Genelabs contributed roughly $4.9 mil. as well as "certain technologies" to the initial financing. Taiwan contributed $5.7 mil.; investors added $4 mil. An investment plan announced in July calls for a total capitalization of about $32.4 mil. "including cash and technology." The balance of commitments will be invested within two years "under certain conditions," Genelabs states...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.